Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Hims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Dr Lotte Knudson, a scientist from Copenhagen, revolutionized research into drugs used by millions to lose weight. She has ...

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the presentation of two abstracts at Obesity Week 2024, the annual meeting of The Obesity Society. The ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...